SMILES,CID,CID (canonical),CID (old format),Postera Link,InChIKey,Submission Creator,Submission Rationale,Submission Notes,Submission Fragments,Structure ID,Fragalysis Link,Enamine - REAL Space,Enamine - Extended REAL Space,Enamine - SCR,Enamine - BB,Mcule,Mcule Ultimate,In Molport or Mcule,In eMolecules,Ordered,Made,Assayed,MW,cLogP,TPSA,Rotatable Bonds,Fraction sp3,HBA,HBD,Covalent Fragment,Covalent Warhead,Acrylamide,Acrylamide Adduct,Chloroacetamide,Chloroacetamide Adduct,Vinylsulfonamide,Vinylsulfonamide Adduct,Nitrile,Nitrile Adduct,r_inhibition_at_20_uM,r_inhibition_at_50_uM,r_avg_IC50,f_inhibition_at_20_uM,f_inhibition_at_50_uM,f_avg_IC50,f_avg_pIC50,relative_solubility_at_20_uM,relative_solubility_at_100_uM,trypsin_IC50,NMR_std_ratio,series,Order Date,Maker,Shipment Date,inspired_by
O=C(Nc1cnc2ccc(F)cn12)C1CCc2cc(Cl)c(Cl)cc21,JUL-TUD-ba2aea69-1,JUL-TUD-ba2aea69-1,,https://covid.postera.ai/covid/submissions/ba2aea69-8f6a-47db-bb8b-e2618f799110/1,UZJPQYDYCHQFFH-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,363.03,4.45,46.4,2,0.18,3,1,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,3-aminopyridine-like,,,,
O=C(Nc1cnc2ccc(F)cn12)C1CCc2cc(Cl)c(Cl)cc21,JUL-TUD-06b2044f-1,JUL-TUD-ba2aea69-1,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/1,UZJPQYDYCHQFFH-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,363.03,4.45,46.4,2,0.18,3,1,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,3-aminopyridine-like,,,,
O=C(Nc1cnn2ccncc12)C1CCc2cc(Cl)c(Cl)cc21,JUL-TUD-06b2044f-2,JUL-TUD-06b2044f-2,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/2,ZKDAOGDSSDVYSU-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,346.04,3.7,59.29,2,0.19,4,1,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,3-aminopyridine-like,,,,
Cc1cc2ncc(NC(=O)C3CCc4cc(Cl)c(Cl)cc43)n2nc1C,JUL-TUD-06b2044f-3,JUL-TUD-06b2044f-3,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/3,HDLWBKZPJMWTFZ-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,374.07,4.32,59.29,2,0.28,4,1,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,3-aminopyridine-like,,,,
Cc1c(Cl)c(Cl)cc2c1OCC(C)C2C(=O)Nc1cnc2n1CCC2,JUL-TUD-06b2044f-4,JUL-TUD-06b2044f-4,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/4,XXJBVEVNWSBKAD-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,379.09,4.2,56.15,2,0.44,4,1,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,3-aminopyridine-like,,,,
O=C(Nc1cnn(CC2CCOC2)c1)C1Cc2cc(Cl)c(Cl)cc21,JUL-TUD-06b2044f-5,JUL-TUD-06b2044f-5,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/5,DJCPQCZSPKIESL-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,365.07,3.5,56.15,4,0.41,4,1,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,3-aminopyridine-like,,,,
CC1COc2c(F)cc(Cl)cc2C1C(=O)Nc1cnc2c(F)cccn12,JUL-TUD-06b2044f-6,JUL-TUD-06b2044f-6,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/6,BWIFNIZNNBPBSP-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,377.07,4.02,55.63,2,0.22,4,1,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,3-aminopyridine-like,,,,
CC1COc2cc(Cl)c(Cl)cc2C1C(=O)Nc1cnnn1CC1CC1,JUL-TUD-06b2044f-7,JUL-TUD-06b2044f-7,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/7,IZULAKIHRIXFFK-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,380.08,3.75,69.04,4,0.47,5,1,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,3-aminopyridine-like,,,,
CCn1nncc1NC(=O)C1c2cc(Cl)c(Cl)cc2OCC1C,JUL-TUD-06b2044f-8,JUL-TUD-06b2044f-8,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/8,NTFSQBDMFFKGBG-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,354.07,3.36,69.04,3,0.4,5,1,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,3-aminopyridine-like,,,,
CCOc1c(Cl)cc(Cl)cc1CC(=O)Nc1nnc(C)cc1C#N,JUL-TUD-06b2044f-9,JUL-TUD-06b2044f-9,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/9,GDQSJRQWFBJEOI-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,364.05,3.54,87.9,5,0.25,5,1,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,3-aminopyridine-like,,,,
Cn1ncc(NC(=O)C2COc3cc(Cl)c(Cl)cc32)c1C1CC1,JUL-TUD-06b2044f-10,JUL-TUD-06b2044f-10,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/10,VAMWTYKUQDYNGV-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,351.05,3.72,56.15,3,0.38,4,1,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,3-aminopyridine-like,,,,
CN1CC(C(=O)Nc2cnn(C)c2C2CC2)Cc2cc(Cl)c(Cl)cc21,JUL-TUD-06b2044f-11,JUL-TUD-06b2044f-11,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/11,MGBMFSFGLGTDEQ-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,378.1,3.85,50.16,3,0.44,4,1,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,,,,,
CN1CCc2c(NC(=O)C3CCc4ccc(Cl)c(Cl)c43)cncc21,JUL-TUD-06b2044f-12,JUL-TUD-06b2044f-12,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/12,ZAGWKMFADAKWLT-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,361.07,4.05,45.23,2,0.33,3,1,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,3-aminopyridine-like,,,,
COc1c(Cl)cc(Cl)c2c1C(C(=O)Nc1cnn3ccccc13)CC2,JUL-TUD-06b2044f-13,JUL-TUD-06b2044f-13,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/13,GMHMJFPNYSKEST-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,375.05,4.32,55.63,3,0.22,4,1,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,3-aminopyridine-like,,,,
O=C1C(c2ccc(Cl)c(Cl)c2)CCN1c1cnc2cccnn12,JUL-TUD-06b2044f-14,JUL-TUD-06b2044f-14,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/14,SSOBGYAXIMYXMZ-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,346.04,3.56,50.5,2,0.19,4,0,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,3-aminopyridine-like,,,,
Cc1[nH]ncc1N1CCC(c2ccc(Cl)c(Cl)c2)C1=O,JUL-TUD-06b2044f-15,JUL-TUD-06b2044f-15,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/15,KEGJQWLIFKOFKR-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,309.04,3.55,48.99,2,0.29,2,1,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,3-aminopyridine-like,,,,
Cn1cc(N2CCC(c3ccc(Cl)c(Cl)c3)C2=O)c(C(C)(C)C)n1,JUL-TUD-06b2044f-16,JUL-TUD-06b2044f-16,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/16,PAPTWLBQTIZDHP-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,365.11,4.54,38.13,2,0.44,3,0,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,3-aminopyridine-like,,,,
Cc1cc2c(c(C)c1Cl)C(C(=O)Nc1ncnc3cn(C)nc13)CCO2,JUL-TUD-06b2044f-17,JUL-TUD-06b2044f-17,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/17,JIRFSTVATKRZDI-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,371.11,3.14,81.93,2,0.33,6,1,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,3-aminopyridine-like,,,,
Cc1nn(CC2CC2)cc1NC(=O)Cc1cc(Cl)c(Cl)cc1F,JUL-TUD-06b2044f-18,JUL-TUD-06b2044f-18,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/18,UNFUBUTYDRFYBW-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,355.07,4.23,46.92,5,0.38,3,1,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,3-aminopyridine-like,,,,
O=C(Cc1cc(Cl)c(F)cc1Cl)Nc1ncnc2c(F)c(F)cc(F)c12,JUL-TUD-06b2044f-19,JUL-TUD-06b2044f-19,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/19,DKIYVBYJAIYOMT-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,402.99,4.67,54.88,3,0.06,3,1,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,3-aminopyridine-like,,,,
O=C(Cc1cc(Cl)cc(Cl)c1F)Nc1nccn2ncnc12,JUL-TUD-06b2044f-20,JUL-TUD-06b2044f-20,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/20,SFXZCSFUHJRMHK-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,339.01,2.75,72.18,3,0.08,5,1,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,3-aminopyridine-like,,,,
O=C(Nc1cnc2n1CCCC2)C1Cc2c(F)cc(Cl)c(Cl)c21,JUL-TUD-06b2044f-21,JUL-TUD-06b2044f-21,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/21,PUGUITMNIJEULJ-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,353.05,3.94,46.92,2,0.38,3,1,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,3-aminopyridine-like,,,,
O=C(Nc1cnn2c1CCCC2)C1Cc2cc(Cl)c(Cl)cc21,JUL-TUD-06b2044f-22,JUL-TUD-06b2044f-22,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/22,WGKNJCLKAMJFFI-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,335.06,3.8,46.92,2,0.38,3,1,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,3-aminopyridine-like,,,,
O=C(Nc1cnn2c1CCCC2)C1CCc2cc(Cl)c(Cl)cc21,JUL-TUD-06b2044f-23,JUL-TUD-06b2044f-23,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/23,UWTYJUSVQQWNRU-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,349.07,4.19,46.92,2,0.41,3,1,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,3-aminopyridine-like,,,,
O=C(Nn1nncc1C1CC1)C1COc2cc(Br)c(Cl)cc21,JUL-TUD-06b2044f-24,JUL-TUD-06b2044f-24,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/24,JPFUDTYPBSAOLB-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,381.98,2.82,69.04,3,0.36,5,1,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,3-aminopyridine-like,,,,
O=C(Nn1nncc1C1CC1)C1COc2cc(Cl)c(Cl)cc21,JUL-TUD-06b2044f-25,JUL-TUD-06b2044f-25,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/25,XXNDJDOKHTZBKT-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,338.03,2.71,69.04,3,0.36,5,1,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,3-aminopyridine-like,,,,
CC(C)(NC(=O)Cc1noc2ccc(F)cc12)c1cccc(Cl)c1Cl,JUL-TUD-06b2044f-26,JUL-TUD-06b2044f-26,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/26,DNSYVDPHIVTNHB-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,380.05,4.87,55.13,4,0.22,3,1,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,,,,,
COc1c(F)cc(F)c(F)c1CNC(=O)C1COc2cc(Cl)c(Cl)cc21,JUL-TUD-06b2044f-27,JUL-TUD-06b2044f-27,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/27,NFGINMHORGHTKA-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,405.01,4.21,47.56,4,0.24,3,1,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,,,,,
CCn1nc(C)c(CC(=O)NCc2cc(Cl)c(Cl)cc2OC)c1C,JUL-TUD-06b2044f-28,JUL-TUD-06b2044f-28,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/28,SNAKLAIFSARPBE-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,369.1,3.69,56.15,6,0.41,4,1,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,,,,,
O=C(c1ccsc1)N1CCN(Cc2cc(Cl)c(Cl)cc2F)CC1,JUL-TUD-06b2044f-29,JUL-TUD-06b2044f-29,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/29,LJPXIUFOMAOZIZ-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,372.03,4.15,23.55,3,0.31,3,0,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,,,,,
Cc1ccc(C(=O)N2CCN(Cc3cc(Cl)c(Cl)cc3F)CC2)s1,JUL-TUD-06b2044f-30,JUL-TUD-06b2044f-30,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/30,UWPLZCXREMFYQA-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,386.04,4.46,23.55,3,0.35,3,0,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,,,,,
O=C(Cc1c(F)cc(F)cc1F)NC1CCOc2cc(Cl)c(Cl)cc21,JUL-TUD-06b2044f-31,JUL-TUD-06b2044f-31,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/31,NYNIUOJEZQBTJM-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,389.02,4.59,38.33,3,0.24,2,1,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,3-aminopyridine-like,,,,
O=C(Cc1cc(Cl)c(F)cc1F)NC1CCOc2cc(Cl)c(F)cc21,JUL-TUD-06b2044f-32,JUL-TUD-06b2044f-32,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/32,HYTLXBOTARBRJR-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,389.02,4.59,38.33,3,0.24,2,1,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,3-aminopyridine-like,,,,
CCOc1cc(Cl)c(Cl)cc1CNC(=O)Cc1nc(C)c(C)s1,JUL-TUD-06b2044f-33,JUL-TUD-06b2044f-33,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/33,NUPVMTHTYLYFNN-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,372.05,4.32,51.22,6,0.38,4,1,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,,,,,
CCOc1cc(Cl)c(Cl)cc1CNC(=O)CCn1nc(C)cc1C,JUL-TUD-06b2044f-34,JUL-TUD-06b2044f-34,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/34,ISEHYDXYZSBCSX-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,369.1,3.91,56.15,7,0.41,4,1,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,,,,,
COc1cc(Cl)c(Cl)cc1CNC(=O)Cc1cn(C)c2cccc(F)c12,JUL-TUD-06b2044f-35,JUL-TUD-06b2044f-35,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/35,RNKBPUKRBYGIOY-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,394.07,4.49,43.26,5,0.21,3,1,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,,,,,
O=C(Cc1cc(Cl)c(F)cc1F)NC1COc2cc(Cl)cc(F)c21,JUL-TUD-06b2044f-36,JUL-TUD-06b2044f-36,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/36,NPHVAWCOQPLUDP-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,375,4.2,38.33,3,0.19,2,1,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,3-aminopyridine-like,,,,
O=C(Cc1cc(Cl)c(F)cc1F)NC1COc2nccc(Cl)c21,JUL-TUD-06b2044f-37,JUL-TUD-06b2044f-37,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/37,SIACRWUTVRZWKU-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,358.01,3.46,51.22,3,0.2,3,1,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,3-aminopyridine-like,,,,
COc1ccc(Cl)c(C)c1CNC(=O)Cc1cc(Cl)cs1,JUL-TUD-06b2044f-38,JUL-TUD-06b2044f-38,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/38,GLKVPDLFSCNIGU-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,343.02,4.23,38.33,5,0.27,3,1,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,,,,,
O=C(Cc1cc(Cl)c(F)cn1)NC1COc2c(F)cc(F)cc21,JUL-TUD-06b2044f-39,JUL-TUD-06b2044f-39,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/39,DZUZCZSFRNFMNZ-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,342.04,2.94,51.22,3,0.2,3,1,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,3-aminopyridine-like,,,,
C#Cc1cccc2cncc(CCNC(=O)C3CCc4cc(Cl)c(Cl)cc43)c12,JUL-TUD-06b2044f-40,JUL-TUD-06b2044f-40,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/40,UOOKLGHKEFCAPT-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,408.08,4.91,41.99,4,0.22,2,1,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,,,,,
O=C(NCCOc1cncc2cnccc12)C1COc2cc(Cl)c(Cl)cc21,JUL-TUD-06b2044f-41,JUL-TUD-06b2044f-41,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/41,KAVUYOSDZDPUAW-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,403.05,3.61,73.34,5,0.21,5,1,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,,,,,
O=C(NCCOc1cncc2cccnc12)C1CCc2cc(Cl)c(Cl)cc21,JUL-TUD-06b2044f-42,JUL-TUD-06b2044f-42,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/42,SCWXCNQIXSWFJK-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,401.07,4.16,64.11,5,0.25,4,1,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,,,,,
CC(C)(C)c1ccc(N(Cc2cccc(Cl)c2)C(=O)Cc2cn[nH]c2)cc1,JUL-TUD-06b2044f-43,JUL-TUD-06b2044f-43,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/43,SYPUBPLKASNEIJ-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,381.16,5.14,48.99,5,0.27,2,1,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,3-aminopyridine-like,,,,
O=C(Nc1cncc2n[nH]cc12)C1Cc2cc(Cl)c(Cl)cc21,JUL-TUD-06b2044f-44,JUL-TUD-06b2044f-44,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/44,BVKCPLAQFVZHOK-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,332.02,3.54,70.67,2,0.13,3,2,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,3-aminopyridine-like,,,,
CC1(C)CCN(C(=O)Nc2cncc3cnccc23)c2cc(Cl)c(Cl)cc21,JUL-TUD-06b2044f-45,JUL-TUD-06b2044f-45,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/45,GDEHEZSYGDPYOO-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,400.09,5.66,58.12,1,0.25,3,1,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,3-aminopyridine-like,,,,
CC(C)CN1CC(C(=O)Nc2cncc3cnccc23)c2cc(Cl)c(Cl)cc21,JUL-TUD-06b2044f-46,JUL-TUD-06b2044f-46,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/46,OHCINICISOMWHW-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,414.1,5.13,58.12,4,0.29,4,1,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,3-aminopyridine-like,,,,
O=C(Nc1cncc2cnccc12)C1CCN(Cc2c(F)cc(Cl)cc2Cl)C1,JUL-TUD-06b2044f-47,JUL-TUD-06b2044f-47,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/47,QQINKCNBTLJKEX-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,418.08,4.54,58.12,4,0.25,4,1,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,,,,,
COC(=O)N1CC(N2CCC(c3ccc(Cl)c(Cl)c3)C2=O)C1,JUL-TUD-06b2044f-48,JUL-TUD-06b2044f-48,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/48,DPMVMNRBEGSQQZ-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,342.05,2.76,49.85,2,0.47,3,0,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,3-aminopyridine-like,,,,
O=C(Nc1cncc2c1CCC2)C1Cc2c(Cl)cc(Cl)cc21,JUL-TUD-06b2044f-49,JUL-TUD-06b2044f-49,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/49,FXUZMSVKDBIMGW-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,332.05,4.16,41.99,2,0.29,2,1,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,3-aminopyridine-like,,,,
O=C(Nc1cncc2c1OCC2)C1Cc2cc(Cl)c(Cl)cc21,JUL-TUD-06b2044f-50,JUL-TUD-06b2044f-50,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/50,UUACSGBTXPCJEW-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,334.03,3.6,51.22,2,0.25,3,1,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,3-aminopyridine-like,,,,
CC1(C(=O)Nc2cncc3cnccc23)CC1c1cc(Cl)cc(Cl)c1,JUL-TUD-06b2044f-51,JUL-TUD-06b2044f-51,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/51,IVEVUAWEHKRAKI-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,371.06,5.07,54.88,3,0.21,3,1,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,,,,,
CC1CN(C(=O)Cc2cncc3ccccc23)Cc2ccc(Cl)c(Cl)c21,JUL-TUD-06b2044f-52,JUL-TUD-06b2044f-52,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/52,XNDFWESPPJGPSP-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,384.08,5.23,33.2,2,0.24,2,0,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,,,,,
O=C1CC(CN(Cc2cccc(Cl)c2Cl)C(=O)Cc2cncc3ccccc23)CCN1,JUL-TUD-06b2044f-53,JUL-TUD-06b2044f-53,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/53,NRPVSWIUKUDZNM-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,455.12,4.64,62.3,6,0.29,3,1,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,,,,,
CC1CN(C(=O)Nc2cncc3ccccc23)CC1c1ccc(Cl)c(Cl)c1,JUL-TUD-06b2044f-54,JUL-TUD-06b2044f-54,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/54,JHLNNJMXEKLNBK-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,399.09,5.81,45.23,2,0.24,2,1,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,,,,,
CCn1cncc1NC(=O)C1c2cc(Cl)cc(Cl)c2OCC1C,JUL-TUD-06b2044f-55,JUL-TUD-06b2044f-55,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/55,RQJHOJVIVGEDML-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,353.07,3.96,56.15,3,0.38,4,1,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,3-aminopyridine-like,,,,
CCOc1c(Cl)cc(Cl)cc1CNc1cncc(C2CC2)c1,JUL-TUD-06b2044f-56,JUL-TUD-06b2044f-56,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/56,CJLIJXMXYJESFM-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,336.08,5.28,34.15,6,0.35,3,1,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,,,,,
O=C(c1cccnc1)N1CCN(Cc2cc(Cl)cc(Cl)c2OC(F)F)CC1,JUL-TUD-06b2044f-57,JUL-TUD-06b2044f-57,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/57,UXYNEMOAHBVIGV-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,415.07,3.95,45.67,5,0.33,4,0,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,,,,,
O=C(NCC1CCCO1)C1CCN(C(=O)c2ccc(Cl)c(Cl)c2)C1,JUL-TUD-06b2044f-58,JUL-TUD-06b2044f-58,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/58,ISBTZUCXEVPYSI-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,370.09,2.75,58.64,4,0.53,3,1,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,,,,,
COc1cc(Cl)c(Cl)cc1CC(=O)Nc1cnnn1C1CC1,JUL-TUD-06b2044f-59,JUL-TUD-06b2044f-59,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/59,BMFFFHRABMROKR-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,340.05,3.11,69.04,5,0.36,5,1,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,3-aminopyridine-like,,,,
CNc1cncnc1NC(=O)C1Cc2cc(Cl)c(Cl)cc21,JUL-TUD-06b2044f-60,JUL-TUD-06b2044f-60,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/60,ZDKZPNDDZRXXQH-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,322.04,3.1,66.91,3,0.21,4,2,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,3-aminopyridine-like,,,,
CCn1ncc2c(NC(=O)C3Cc4cc(Cl)c(Cl)cc43)nncc21,JUL-TUD-06b2044f-61,JUL-TUD-06b2044f-61,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/61,NDDKEWXCIBODJI-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,361.05,3.43,72.7,3,0.25,5,1,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,3-aminopyridine-like,,,,
COCCCn1ncc2c(NC(=O)C3Cc4cc(Cl)c(Cl)cc43)nncc21,JUL-TUD-06b2044f-62,JUL-TUD-06b2044f-62,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/62,QLBWULIAFSNSCY-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,405.08,3.45,81.93,6,0.33,6,1,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,3-aminopyridine-like,,,,
CCn1ncc2c(NC(=O)C3CCOc4cc(Cl)c(Cl)cc43)nncc21,JUL-TUD-06b2044f-63,JUL-TUD-06b2044f-63,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/63,DLFLUPRSGUTFCI-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,391.06,3.66,81.93,3,0.29,6,1,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,3-aminopyridine-like,,,,
CN(C(=O)C1CN(C2CCCC2)c2cc(Cl)c(Cl)cc21)c1cncnc1,JUL-TUD-06b2044f-64,JUL-TUD-06b2044f-64,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/64,IBXIREFDEFAOJM-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,390.1,4.29,49.33,3,0.42,4,0,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,3-aminopyridine-like,,,,
CN(Cc1ccc(Cl)c(Cl)c1)C(=O)CC1CCNC1=O,JUL-TUD-06b2044f-65,JUL-TUD-06b2044f-65,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/65,DLWLEVAATDSTAB-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,314.06,2.48,49.41,4,0.43,2,1,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,,,,,
CN1CC(CNC(=O)C2CCOc3cc(F)c(Cl)cc32)C1,JUL-TUD-06b2044f-66,JUL-TUD-06b2044f-66,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/66,BTCQEOOYOUEXKS-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,312.1,2.02,41.57,3,0.53,3,1,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,,,,,
O=C(CN1CCN(Cc2ccc(Cl)c(Cl)c2)C1=O)Nc1cncc2c1CCN2,JUL-TUD-06b2044f-67,JUL-TUD-06b2044f-67,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/67,AWDBBZQDACJKGR-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,419.09,3.23,77.57,5,0.32,4,2,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,3-aminopyridine-like,,,,
O=C(Cc1ccc(Cl)c(Cl)c1)Nc1cnnn1C1CCOCC1,JUL-TUD-06b2044f-68,JUL-TUD-06b2044f-68,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/68,VXQBEJVGQQIDCN-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,354.07,3.12,69.04,4,0.4,5,1,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,3-aminopyridine-like,,,,
COc1c(Cl)c(Cl)cc2c1C(C)C(C(=O)NCc1cncc3ccccc13)O2,JUL-TUD-06b2044f-69,JUL-TUD-06b2044f-69,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/69,IJPKLTLLMJBKRT-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,416.07,4.73,60.45,4,0.24,4,1,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,,,,,
COc1c(Cl)cc(Cl)cc1CN(CC1COC1)C(=O)Cn1nnc2c1CCCC2,JUL-TUD-06b2044f-70,JUL-TUD-06b2044f-70,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/70,WMTMJBFMHRGKIE-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,438.12,3.15,69.48,7,0.55,6,0,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,,,,,
COc1c(Cl)cc(Cl)cc1CN1CCN(CC2CCC(=O)N2)CC1=O,JUL-TUD-06b2044f-71,JUL-TUD-06b2044f-71,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/71,GLFBDCBLVFIXBZ-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,385.1,1.92,61.88,5,0.53,4,1,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,,,,,
O=C(c1cncc2ccc(F)cc12)N1CCN(Cc2ccc(Cl)cc2Cl)CC1,JUL-TUD-06b2044f-72,JUL-TUD-06b2044f-72,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/72,WGBIKPCBZHDKAT-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,417.08,4.64,36.44,3,0.24,3,0,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,,,,,
COc1c(Cl)cc(Cl)cc1CN1CCN(C(=O)c2cncc3ccc(F)cc23)CC1,JUL-TUD-06b2044f-73,JUL-TUD-06b2044f-73,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/73,KZOGULGMRPFXRB-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,447.09,4.65,45.67,4,0.27,4,0,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,,,,,
COc1ccc2cncc(C(=O)N3CCN(Cc4cc(Cl)ccc4Cl)CC3)c2c1,JUL-TUD-06b2044f-74,JUL-TUD-06b2044f-74,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/74,VVSLKCKIJZZXJS-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,429.1,4.51,45.67,4,0.27,4,0,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,,,,,
COc1c(Cl)cc(Cl)cc1CS(=O)(=O)N1CCN(c2c(F)ncc3ccccc23)C1=O,JUL-TUD-06b2044f-75,JUL-TUD-06b2044f-75,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/75,ASGWHJSGSZKULY-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,483.02,4.46,79.81,5,0.2,5,0,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,,,,,
O=C(Nc1cncs1)C1COc2c(F)c(Cl)cc(Cl)c21,JUL-TUD-06b2044f-76,JUL-TUD-06b2044f-76,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/76,FYSWDYQXCRMMEH-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,331.96,3.7,51.22,2,0.17,4,1,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,3-aminopyridine-like,,,,
COc1cc(Cl)c(Cl)c2c1N(C(=O)Nc1cncc3ccc(C4CC4)cc13)CC2,JUL-TUD-06b2044f-77,JUL-TUD-06b2044f-77,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/77,MJZCPZFLMJWFTJ-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,427.09,6.02,54.46,3,0.27,3,1,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,3-aminopyridine-like,,,,
COc1cc(Cl)c(Cl)cc1CN1CCC(Cc2cccnc2)C1=O,JUL-TUD-06b2044f-78,JUL-TUD-06b2044f-78,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/78,QWIKMPDKHONMBV-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,364.07,3.99,42.43,5,0.33,3,0,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,,,,,
O=C1C(c2ccc(Cl)c(Cl)c2)CCN1c1cnnnc1,JUL-TUD-06b2044f-79,JUL-TUD-06b2044f-79,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/79,LBDMTFPHFRWXNS-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,308.02,2.7,58.98,2,0.23,4,0,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,3-aminopyridine-like,,,,
COc1cc2cncc(C(=O)NCc3cc(Cl)cc(Cl)c3)c2cc1OC,JUL-TUD-06b2044f-80,JUL-TUD-06b2044f-80,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/80,IDCGHRYGWDIGQE-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,390.05,4.49,60.45,5,0.16,4,1,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,,,,,
COc1ncncc1N1CCN(Cc2cc(Cl)cc(Cl)c2OC)C1=O,JUL-TUD-06b2044f-81,JUL-TUD-06b2044f-81,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/81,HGVKIMKDWVPDAG-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,382.06,3.24,67.79,5,0.31,5,0,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,,,,,
O=C(Cn1ncc2cccnc21)NCc1cc(F)c(Cl)cc1Cl,JUL-TUD-06b2044f-82,JUL-TUD-06b2044f-82,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/82,KGLSJJTVSLEOJH-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,352.03,3.19,59.81,4,0.13,4,1,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,,,,,
Cc1cc(Cl)c(Cl)cc1C(=O)N1CCCC1(C)C(=O)Nc1cncc2ccccc12,JUL-TUD-06b2044f-83,JUL-TUD-06b2044f-83,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/83,AQHHUQLZNQBALN-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,441.1,5.48,62.3,3,0.26,3,1,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,Ugi,,,,
Cc1ccnn1-c1cc(Cl)cc(Cl)c1OCC(=O)Nc1cncc2cnccc12,JUL-TUD-06b2044f-84,JUL-TUD-06b2044f-84,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/84,QVCYVDAZEPABMK-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,427.06,4.45,81.93,5,0.1,6,1,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,,,,,
O=C(Cn1cncn1)N1CCN(Cc2ccc(Cl)c(Cl)c2)CC1,JUL-TUD-06b2044f-85,JUL-TUD-06b2044f-85,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/85,DSQAKWKNKNZXBN-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,353.08,1.93,54.26,4,0.4,5,0,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,,,,,
O=C(Cc1cc(Cl)c(F)cc1Cl)Nc1cnnn1CC1CC1,JUL-TUD-06b2044f-86,JUL-TUD-06b2044f-86,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/86,RIINTRBWCZCXQY-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,342.05,3.32,59.81,5,0.36,4,1,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,3-aminopyridine-like,,,,
O=C(Nc1cncn1CC1CC1)C1COc2ccc(Cl)c(Cl)c21,JUL-TUD-06b2044f-87,JUL-TUD-06b2044f-87,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/87,WTSHFSCHAMUQPO-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,351.05,3.71,56.15,4,0.38,4,1,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,3-aminopyridine-like,,,,
Cc1nnc2cncc(NC(=O)C3COc4ccc(Cl)c(Cl)c43)n12,JUL-TUD-06b2044f-88,JUL-TUD-06b2044f-88,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/88,WZYNOZZVDGTKCS-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,363.03,2.85,81.41,2,0.2,6,1,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,3-aminopyridine-like,,,,
O=C1N(CCC2CCc3cc(Cl)c(Cl)cc3C2)CCN1c1cncc2ccccc12,JUL-TUD-06b2044f-89,JUL-TUD-06b2044f-89,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/89,OZTLQPHCJVJQSG-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,439.12,5.98,36.44,4,0.33,2,0,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,,,,,
Cn1cc(N(Cc2cccnc2)C(=O)C2CCOc3cc(F)c(Cl)cc32)cn1,JUL-TUD-06b2044f-90,JUL-TUD-06b2044f-90,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/90,MROUZLYKQWRMEO-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,400.11,3.71,60.25,4,0.25,5,0,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,3-aminopyridine-like,,,,
N#Cc1ccc(CN2CCN(c3cncnc3)C2=O)c(Cl)c1,JUL-TUD-06b2044f-91,JUL-TUD-06b2044f-91,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/91,KNYIRXIVSUEVKE-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,313.07,2.44,73.12,3,0.2,4,0,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,,,,,
Cn1cnc2c(N3CCN(Cc4cc(Cl)c(Cl)cc4F)C3=O)cncc21,JUL-TUD-06b2044f-92,JUL-TUD-06b2044f-92,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/92,QBXSWFBRWBVALS-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,393.06,3.86,54.26,3,0.24,4,0,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,,,,,
Cn1ncc2c(NC(=O)C3Cc4c(ccc(Cl)c4Cl)O3)cncc21,JUL-TUD-06b2044f-93,JUL-TUD-06b2044f-93,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/93,JRIOLSJZBGVUCK-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,362.03,3.22,69.04,2,0.19,5,1,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,,,,,
Cn1nncc1NC(=O)Cc1c(Cl)ccc(Cl)c1OCC1CCO1,JUL-TUD-06b2044f-94,JUL-TUD-06b2044f-94,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/94,CNGKYZDGWOQIRG-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,370.06,2.47,78.27,6,0.4,6,1,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,3-aminopyridine-like,,,,
O=C(Cc1cc(Cl)c(F)cc1F)Nc1cncc2c1cnn2CC1CCO1,JUL-TUD-06b2044f-95,JUL-TUD-06b2044f-95,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/95,USCHQJCUDLEFGI-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,392.09,3.33,69.04,5,0.28,5,1,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,3-aminopyridine-like,,,,
O=C(Cc1cc(Cl)cc(Cl)c1F)Nc1cnn2ccncc12,JUL-TUD-06b2044f-96,JUL-TUD-06b2044f-96,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/96,MRLQFSKPWOEICG-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,338.01,3.36,59.29,3,0.07,4,1,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,3-aminopyridine-like,,,,
O=C(Cc1cc(F)c(Cl)cc1Cl)Nn1cnnc1,JUL-TUD-06b2044f-97,JUL-TUD-06b2044f-97,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/97,PLECPYNFWNVWMM-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,288,2.04,59.81,3,0.1,4,1,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,3-aminopyridine-like,,,,
O=C(Cn1cncn1)NCc1cc(F)c(Cl)cc1Cl,JUL-TUD-06b2044f-98,JUL-TUD-06b2044f-98,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/98,LKNYRHYMXWLKCU-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,302.01,2.04,59.81,4,0.18,4,1,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,,,,,
O=C(Cc1cc(F)cc(F)c1F)Nc1cnn(CC2CCOC2)c1,JUL-TUD-06b2044f-99,JUL-TUD-06b2044f-99,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/99,YHWKFVKGORBXKR-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,339.12,2.52,56.15,5,0.38,4,1,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,3-aminopyridine-like,,,,
O=C(Cc1ccc(Cl)c(Cl)c1)N1CCNCC1Cn1ccnn1,JUL-TUD-06b2044f-100,JUL-TUD-06b2044f-100,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/100,NXXBXSVUGPYTJR-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,353.08,1.63,63.05,4,0.4,5,1,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,,,,,
O=C(Cc1cncc(-n2ccnc2)c1)N1CCc2cc(Cl)c(Cl)cc21,JUL-TUD-06b2044f-101,JUL-TUD-06b2044f-101,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/101,BLXAWXWFZGNFPM-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,372.05,3.71,51.02,3,0.17,4,0,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,3-aminopyridine-like,,,,
O=C(NCCn1cnc2ccncc21)C1COc2c(Cl)cc(Cl)cc21,JUL-TUD-06b2044f-102,JUL-TUD-06b2044f-102,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/102,UIBNFXRBTMGXJZ-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,376.05,3.03,69.04,4,0.24,5,1,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,,,,,
O=C(Nc1cncc2c1CCN2CCO)C1COc2c(Cl)cc(Cl)cc21,JUL-TUD-06b2044f-103,JUL-TUD-06b2044f-103,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/103,SPKBYQJZXOVQJE-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,393.06,2.86,74.69,4,0.33,5,2,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,3-aminopyridine-like,,,,
O=C(NCc1cncc2c1CCCC2)C1Cc2c(ccc(Cl)c2F)O1,JUL-TUD-06b2044f-104,JUL-TUD-06b2044f-104,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/104,XMEMUGJUIKQHGF-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,360.1,3.37,51.22,3,0.37,3,1,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,,,,,
O=C(Nc1ccc(F)nc1)C1CCN(C(=O)CC2CCOc3cc(Cl)c(Cl)cc32)C1,JUL-TUD-06b2044f-105,JUL-TUD-06b2044f-105,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/105,NJSTVIWHFRXBGB-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,451.09,4.27,71.53,4,0.38,4,1,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,,,,,
O=C(Nn1cnc2c(F)cc(F)cc21)C1COc2cc(Cl)c(Cl)cc21,JUL-TUD-06b2044f-106,JUL-TUD-06b2044f-106,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/106,CCXRYRUAUVPQMH-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,383,3.87,56.15,2,0.12,4,1,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,3-aminopyridine-like,,,,
O=C1C(c2cc(F)c(F)cc2F)CCCN1c1cncn2cnnc12,JUL-TUD-06b2044f-107,JUL-TUD-06b2044f-107,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/107,NTSIYXPEJRMNIC-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,347.1,2.45,63.39,2,0.25,5,0,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,3-aminopyridine-like,,,,
O=C1C(c2ccc(Cl)c(Cl)c2)CCCN1Cc1c[nH]cn1,JUL-TUD-06b2044f-108,JUL-TUD-06b2044f-108,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/108,BNDFGORGUYQCCX-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,323.06,3.62,48.99,3,0.33,2,1,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,,,,,
O=C1CC(CCc2ccc(Cl)c(Cl)c2)CN1c1cncc2cnccc12,JUL-TUD-06b2044f-109,JUL-TUD-06b2044f-109,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/109,XARREUQUQACZMB-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,385.07,4.92,46.09,4,0.25,3,0,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,,,,,
O=C1N(Cc2cc(Cl)ccc2Cl)CCN1c1cnnc2c(F)cccc12,JUL-TUD-06b2044f-110,JUL-TUD-06b2044f-110,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/110,HYRFUEKCXFRBCY-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,390.05,4.52,49.33,3,0.17,3,0,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,,,,,
O=C1N(Cc2ccccc2Cl)CCN1c1cncc2ccc(Cl)cc12,JUL-TUD-06b2044f-111,JUL-TUD-06b2044f-111,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/111,GZMTUKIKBILMTO-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,371.06,4.98,36.44,3,0.16,2,0,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,,,,,
O=C1N(Cc2ccc(Cl)cc2Cl)CCN1c1cncc2ccccc12,JUL-TUD-06b2044f-112,JUL-TUD-06b2044f-112,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/112,JXAJMGFDBKJQCX-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,371.06,4.98,36.44,3,0.16,2,0,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,,,,,
O=C1NCc2c(NC(=O)N3CCc4c(Cl)ccc(Cl)c43)cncc21,JUL-TUD-06b2044f-113,JUL-TUD-06b2044f-113,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/113,MWPILLPFOSBTNV-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,362.03,3.23,74.33,1,0.19,3,2,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,3-aminopyridine-like,,,,
CCN(Cc1cc(Cl)c(Cl)cc1OC)C(=O)C1CCN(C(C)=O)C1,JUL-TUD-06b2044f-114,JUL-TUD-06b2044f-114,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/114,GCOPUOAPWHAWAP-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,372.1,3.22,49.85,5,0.53,3,0,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,,,,,
CCn1cnnc1CNC(=O)Cc1cc(F)c(Cl)cc1Cl,JUL-TUD-06b2044f-115,JUL-TUD-06b2044f-115,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/115,BBYSOKIUMLXCAX-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,330.05,2.6,59.81,5,0.31,4,1,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,,,,,
CC(=O)N1CCN(C(=O)Cc2ccc(Cl)c(Cl)c2)C(CN2CCOC2=O)C1,JUL-TUD-06b2044f-116,JUL-TUD-06b2044f-116,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/116,LKWWSZRDZHLWPK-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,413.09,2.05,70.16,4,0.5,4,0,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,,,,,
O=C(Cc1cc(Cl)c(Cl)cc1F)NCCC(O)c1cncnc1,JUL-TUD-06b2044f-117,JUL-TUD-06b2044f-117,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/117,KAPOQXAADAUQHX-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,357.04,2.7,75.11,6,0.27,4,2,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,,,,,
O=C(Cc1ccc(F)c(F)c1)NCC1(c2ccc(Cl)c(Cl)c2)CCOCC1,JUL-TUD-06b2044f-118,JUL-TUD-06b2044f-118,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/118,RDDWWWAPCASVFJ-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,413.08,4.68,38.33,5,0.35,2,1,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,,,,,
Cn1cc(C(=O)N2CCN(Cc3cc(Cl)cc(Cl)c3F)CC2)cn1,JUL-TUD-06b2044f-119,JUL-TUD-06b2044f-119,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/119,NFOSOQFKNDEFAP-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,370.08,2.82,41.37,3,0.38,4,0,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,,,,,
O=C(Cc1cc(F)cc(F)c1)NCc1cc(Cl)c(Cl)cc1-n1cncn1,JUL-TUD-06b2044f-120,JUL-TUD-06b2044f-120,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/120,MCEPLFUBFKPPBW-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,396.04,3.71,59.81,5,0.12,4,1,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,,,,,
CN(C(=O)Cc1cc(F)c(F)cc1F)C(CCO)c1ccc(F)c(Cl)c1,JUL-TUD-06b2044f-121,JUL-TUD-06b2044f-121,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/121,HREFUNZBQBVNRA-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,389.08,4.02,40.54,6,0.28,2,1,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,,,,,
CC1CN(C(=O)Cc2ccco2)C(C)CN1CCc1cc(F)c(F)cc1F,JUL-TUD-06b2044f-122,JUL-TUD-06b2044f-122,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/122,GNUSFQNQSYKKIH-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,380.17,3.4,36.69,5,0.45,3,0,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,,,,,
CC1c2cc(Cl)c(Cl)cc2C(=O)N1CC(=O)NCc1ccoc1,JUL-TUD-06b2044f-123,JUL-TUD-06b2044f-123,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/123,KWGJZGCFJJIZAS-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,352.04,3.42,62.55,4,0.25,3,1,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,Ugi,,,,
Cc1nnc2n1CC(CNC(=O)Cc1cc(Cl)c(Cl)cc1F)CC2,JUL-TUD-06b2044f-124,JUL-TUD-06b2044f-124,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/124,ASFRFSUQRFPXJG-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,370.08,2.95,59.81,4,0.44,4,1,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,,,,,
Cc1cc(CC(=O)NCc2cc(Cl)c(Cl)cc2-n2ccnc2C)[nH]n1,JUL-TUD-06b2044f-125,JUL-TUD-06b2044f-125,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/125,PUSRLQOERNCNJC-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,377.08,3.38,75.6,5,0.24,4,2,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,,,,,
O=C(c1cccnc1)N1CCN(Cc2cc(Cl)c(Cl)cc2F)CC1,JUL-TUD-06b2044f-126,JUL-TUD-06b2044f-126,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/126,XUWWVMVQIFGSSU-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,367.07,3.49,36.44,3,0.29,3,0,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,,,,,
CCc1nccn1CCC(=O)NCc1cc(Cl)c(Br)cc1F,JUL-TUD-06b2044f-127,JUL-TUD-06b2044f-127,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/127,CKLTYGWNJGJOSS-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,387.01,3.71,46.92,6,0.33,3,1,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,,,,,
O=C(c1cccnc1)N1CCN(Cc2cccc(Cl)c2Cl)CC1,JUL-TUD-06b2044f-128,JUL-TUD-06b2044f-128,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/128,YFCKJNIXJVHXQD-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,349.07,3.35,36.44,3,0.29,3,0,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,,,,,
CCn1cc(CC(=O)NCc2cc(Cl)c(Cl)cc2OC)c2cnccc21,JUL-TUD-06b2044f-129,JUL-TUD-06b2044f-129,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/129,OHPGYEOAQMNIQI-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,391.09,4.23,56.15,6,0.26,4,1,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,,,,,
O=C(Cn1ccnc1)N(Cc1cc(Cl)c(Cl)cc1F)C1CCOCC1,JUL-TUD-06b2044f-130,JUL-TUD-06b2044f-130,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/130,NBNULZSDCCKFJQ-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,385.08,3.54,47.36,5,0.41,4,0,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,,,,,
COCC1c2cnn(C)c2CCN1C(=O)Cc1cc(Cl)c(Cl)cc1F,JUL-TUD-06b2044f-131,JUL-TUD-06b2044f-131,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/131,QPCPKTRTZKPWAU-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,385.08,3.18,47.36,4,0.41,4,0,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,,,,,
COCC1c2cnn(C)c2CCN1C(=O)Cc1cc(F)c(Cl)cc1Cl,JUL-TUD-06b2044f-132,JUL-TUD-06b2044f-132,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/132,UPJYIGBRZJMXLL-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,385.08,3.18,47.36,4,0.41,4,0,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,,,,,
COCCOCC1c2c(ncn2C)CCN1C(=O)Cc1cc(Cl)c(Cl)cc1F,JUL-TUD-06b2044f-133,JUL-TUD-06b2044f-133,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/133,ZZALSBQSNXXVKS-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,429.1,3.2,56.59,7,0.47,5,0,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,,,,,
COc1c(COCC(=O)NC2CCOC2=O)ccc(Cl)c1Cl,JUL-TUD-06b2044f-134,JUL-TUD-06b2044f-134,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/134,VWOCXRTVXMMFED-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,347.03,1.95,73.86,6,0.43,5,1,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,,,,,
O=C(NCc1cc(F)c(F)cc1-c1ccncc1)C1(c2ccc(Cl)c(Cl)c2)CC1,JUL-TUD-06b2044f-135,JUL-TUD-06b2044f-135,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/135,IDXYITPMOKDQDX-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,432.06,5.68,41.99,5,0.18,2,1,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,,,,,
O=C(c1ccoc1)N1CCN(Cc2cc(Cl)cc(Cl)c2F)CC1,JUL-TUD-06b2044f-136,JUL-TUD-06b2044f-136,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/136,WYEVVSYWZSXOQS-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,356.05,3.68,36.69,3,0.31,3,0,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,,,,,
Cc1cc(Cl)c(CNC(=O)CCCc2ccc(F)nc2)cc1Cl,JUL-TUD-06b2044f-137,JUL-TUD-06b2044f-137,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/137,KMZDUFVISAGXNY-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,354.07,4.48,41.99,6,0.29,2,1,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,,,,,
Cc1nc(CC(=O)NCc2ccc(F)c(Cl)c2)no1,JUL-TUD-06b2044f-138,JUL-TUD-06b2044f-138,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/138,KGNOBTMJZUHACN-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,283.05,2.03,68.02,4,0.25,4,1,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,,,,,
Cc1nc(CC(=O)NCc2ccc(Cl)c(Cl)c2-c2cnco2)cs1,JUL-TUD-06b2044f-139,JUL-TUD-06b2044f-139,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/139,GOBHXNNYNNMEAI-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,381.01,4.27,68.02,5,0.19,5,1,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,,,,,
Cc1ccc(CCC(=O)NC2CCOc3cc(Cl)c(Cl)cc32)cn1,JUL-TUD-06b2044f-140,JUL-TUD-06b2044f-140,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/140,GACRUGDKJZDOST-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,364.07,4.27,51.22,4,0.33,3,1,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,,,,,
O=C(Cc1n[nH]c(=O)c2ccc(F)cc12)N(Cc1ccc(Cl)c(Cl)c1)C1CCCC1,JUL-TUD-06b2044f-141,JUL-TUD-06b2044f-141,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/141,MQKJOVRBTMYSAQ-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,447.09,4.88,66.06,5,0.32,3,1,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,3-aminopyridine-like,,,,
O=C1C(N(Cc2ccc(Cl)c(Cl)c2)Cc2ccco2)CCN1Cc1ccccc1,JUL-TUD-06b2044f-142,JUL-TUD-06b2044f-142,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/142,RUHUVIIYDFRCMN-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,428.11,5.39,36.69,7,0.26,3,0,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,,,,,
O=C(NCc1cc(Cl)c(Cl)cc1-n1cncn1)C1COc2ncccc2C1,JUL-TUD-06b2044f-143,JUL-TUD-06b2044f-143,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/143,JPPCEYSDUUNPKY-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,403.06,2.84,81.93,4,0.22,6,1,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,,,,,
Cc1nc(CCNC(=O)C2(c3ccc(Cl)c(Cl)c3)CC2)co1,JUL-TUD-06b2044f-144,JUL-TUD-06b2044f-144,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/144,GETPNMPUTDCQHG-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,338.06,3.68,55.13,5,0.38,3,1,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,,,,,
O=C(Cn1cnnn1)NCc1ccc(Cl)c(Cl)c1,JUL-TUD-06b2044f-145,JUL-TUD-06b2044f-145,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/145,MUVIZVXBIWCHNM-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,285.02,1.3,72.7,4,0.2,5,1,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,,,,,
O=C(Cn1cc(C2CC2)nn1)NCc1ccc(Cl)c(Cl)c1,JUL-TUD-06b2044f-146,JUL-TUD-06b2044f-146,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/146,OIYCLQWYHRFIKF-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,324.05,2.78,59.81,5,0.36,4,1,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,,,,,
Clc1ccc(CN2CCc3nnc(CN4CCOCC4)n3CC2)cc1Cl,JUL-TUD-06b2044f-147,JUL-TUD-06b2044f-147,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/147,WBKJIPOJFODVBB-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,395.13,2.48,46.42,4,0.56,6,0,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,,,,,
Cn1cc(C2COCCN2C(=O)Cc2cc(Cl)c(Cl)cc2F)cn1,JUL-TUD-06b2044f-148,JUL-TUD-06b2044f-148,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/148,CPNXNKZIMYEGJE-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,371.06,3.01,47.36,3,0.38,4,0,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,,,,,
N#Cc1c(F)ccc(CC(=O)NCc2ccc(Cl)c(F)c2-n2cncn2)c1Cl,JUL-TUD-06b2044f-149,JUL-TUD-06b2044f-149,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/149,NDLDBOCTLOMDNR-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,421.03,3.58,83.6,5,0.11,5,1,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,,,,,
O=C(COCc1cc(F)cc(F)c1)NCc1cc(Cl)cc(Cl)c1-n1cncn1,JUL-TUD-06b2044f-150,JUL-TUD-06b2044f-150,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/150,LCPFGVVKZBVYDN-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,426.05,3.69,69.04,7,0.17,5,1,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,,,,,
O=C(Cc1cc(C(=O)N2CCOCC2)[nH]n1)NCc1cc(Cl)cc(F)c1Cl,JUL-TUD-06b2044f-151,JUL-TUD-06b2044f-151,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/151,JKYKIXJKUXWOBZ-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,414.07,2.19,87.32,5,0.35,4,2,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,,,,,
O=C(Cn1nnnc1CN1CCOCC1)NCc1cc(Cl)c(Cl)cc1F,JUL-TUD-06b2044f-152,JUL-TUD-06b2044f-152,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/152,JVUKDQAJONMIPP-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,402.08,1.27,85.17,6,0.47,7,1,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,,,,,
O=C(Cn1nnnc1CN1CCOCC1)NCc1c(Cl)cc(F)cc1Cl,JUL-TUD-06b2044f-153,JUL-TUD-06b2044f-153,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/153,CPOANJBVZBVXCS-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,402.08,1.27,85.17,6,0.47,7,1,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,,,,,
O=C(NCc1cc(Cl)c(Cl)cc1N1CCOCC1)N1CCCC1c1cccnc1,JUL-TUD-06b2044f-154,JUL-TUD-06b2044f-154,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/154,SIXNMOAQNYCIMQ-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,434.13,4.27,57.7,4,0.43,4,1,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,,,,,
O=C(NCc1ccccn1)N1CCc2cc(Cl)c(Cl)cc21,JUL-TUD-06b2044f-155,JUL-TUD-06b2044f-155,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/155,SJMGKSVKKSCTNO-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,321.04,3.66,45.23,2,0.2,2,1,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,,,,,
O=C(NCc1cocn1)NCc1c(F)cc(F)cc1Cl,JUL-TUD-06b2044f-156,JUL-TUD-06b2044f-156,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/156,ZDZKJQKTQSALAO-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,301.04,2.61,67.16,4,0.17,3,2,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,,,,,
O=C(NCc1ncccc1F)NC1CCc2cc(Cl)c(Cl)cc21,JUL-TUD-06b2044f-157,JUL-TUD-06b2044f-157,,https://covid.postera.ai/covid/submissions/06b2044f-e535-4a94-acfd-a6bd7604ec03/157,JUSCWSXOSWGCCN-UHFFFAOYSA-N,"Julien Hazemann, TU-Dortmund & Idorsia Pharmaceuticals Ltd","In the frame of a collaboration with the Czodrowski AG and Idorsia Pharmaceuticals, the submitted compounds were designed with a Deep Generative Model (DGM) using Reinforcement Learning (RL). Using Covid Moonshot data and ChEMBL data, privileged fragments were identified by Matched Molecular Pairs and a scoring components was developed. Crystal structures (Fragalysis data) with non-covalent ligands were selected and used for a shape and 3D-Pharmacophore scoring component. The scoring components were used in RL fashion to train a DGM to generate potential SARS-COV-2 Mpro inhibitors. Molecules were then generated. The molecules were prioritized by Machine Learning for synthesizability and binding affinity. Finally, the generated molecules were further assessed by template docking using 3 selected PDB files (MPro-x12692, MPro-x11294 and Mpro-P0009) covering 3 main series (amino-pyridine, Ugi and quinolone series). 157 molecules were then selected and submitted to Covid Moonshot.",,,,,FALSE,FALSE,FALSE,FALSE,,,,,FALSE,FALSE,FALSE,353.05,4.01,54.02,3,0.25,2,2,,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,,,,,,,,,,,,,,,,,,